Dr Rugo speaks with ecancer at AACR 2017 about the final analysis of MONARCH 1, a phase II trial of abemaciclib for advanced HR /HER2- breast cancer following chemotherapy.
She summarises the cell cycle action of CDK4/6 inhibitors, noting cross-activity with oestrogen receptors, and the differing actions of related treatments ribociclib and palbociclib.
Dr Rugo describes the treatment history of trial participants, and outlines the improvements in PFS with easily-managed adverse effects.
She also notes effects of abemaciclib on kidney tububle function, which is "meaningless on a clinical basis".
MONARCH 1 and further neoMONARCH trials were also discussed by Dr Sara Hurvitz at an ecancer symposium on CDK inhibition at ESMO 2016.